Development of a system of medicine and personalized prescription validated in real clinical conditions in the Spanish Extremadura Health Service, connectable to his electronic prescription system.
It comprises the following components:
(a) the personalized prescription system itself
(b) development of a pharmacogenetic analysis system
(c) evaluation system of patients and volunteers for clinical trials
(d) system for evaluating adverse reactions to drugs.
Global contract value: 2,192K euros
Contracting decision: February 2022
Ending: February 2023
This content is restricted to Investors. If you are an existing investor, please log in.